1. Understand the evolving predictive role of the 21 gene assay in hormone positive breast cancer.
2. Appreciate multiple available adjuvant strategies for optimizing survival outcomes in hormone positive breast cancer.
3. Review pathological guidelines and considerations for diagnosis and management of HER2neu indeterminate breast cancers.
02/16/2021 - 7:00am to 8:00am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Rita Nanda, MD: Associate Professor of Medicine, Director of Breast Oncology Program Jennifer Tseng, MD: Assistant Professor of Surgery Anne McCall, MD: Associate Professor of Radiation and Cellular Oncology, Medical Director, Medical Oncology for Silver